A5033032136- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Testicular diseases and treatments
- Neuroblastoma Research and Treatments
- Multiple and Secondary Primary Cancers
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Cancer therapeutics and mechanisms
- Gestational Trophoblastic Disease Studies
- Economic and Financial Impacts of Cancer
- Urologic and reproductive health conditions
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer and biochemical research
- Multiple Myeloma Research and Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Biosimilars and Bioanalytical Methods
- Genomic variations and chromosomal abnormalities
Azienda Unità Sanitaria Locale Della Romagna
2021-2023
Ospedale "Santa Maria delle Croci" di Ravenna
2001-2023
Ospedale per gli Infermi
2019-2021
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2012
Ospedale Santa Maria
2012
Istituto Oncologico Romagnolo
2004-2009
Indiana University – Purdue University Indianapolis
2007
European School of Oncology
2002
University of L'Aquila
2001
Azienda Ospedaliera Carlo Poma
2001
This study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy locally advanced rectal cancer.The PANDORA trial is a prospective, phase II, open-label, single-arm, multicenter aimed at evaluating and safety preoperative treatment with (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 administered 825 mg/m2 twice daily). The primary...
Abstract Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able predict from immune checkpoint inhibition in triple-negative breast cancer. In this analysis...
LBA3513 Background: The combination of capecitabine plus long course radiotherapy (RT) is the standard preoperative therapy in cT3-4 cN+ rectal cancer. pathologic complete remission (pCR) can be considered as surrogate endpoint efficacy treatment terms disease-free survival (DFS). Preclinical data points heavily toward a strong synergy between RT and immune treatments. Methods: This prospective phase II, open label, single arm, multicentre study patient with locally advanced cancer who...
Abstract BACKGROUND High‐dose chemotherapy (HDCT) followed by hematopoietic stem cell support (HSCS) potentially may be curative in patients with germ tumor (GCT) who develop recurrent tumors or have an inadequate response after receiving standard‐dose chemotherapy. The authors report their experience HDCT as salvage therapy for GCT. METHODS Between 1986 and 2000, 84 GCT, a median age 29 years (range, 15–50 years), were treated 105 courses of HSCS. Patients stratified into good,...
Although the overall cure rate for advanced germ cell tumor (GCT) is high, prognosis patients with cisplatin-refractory GCT remains poor. Gemcitabine, paclitaxel, and oxaliplatin have shown significant activity as single agents in these patients. We investigated tolerance of a weekly gemcitabine, chemotherapy regimen. From September 2000 to February 2002, 9 were treated gemcitabine 800 mg/m2, paclitaxel 70 50 days 1, 8, 15, every 4 weeks. Only 1 patient stayed on schedule. In 7 patients,...
Background Hepatic arterial infusion chemotherapy is a promising approach in liver metastases from colorectal cancer, but chemical hepatitis, biliary sclerosis, thrombosis and right upper quadrant pain are limiting factors. Irinotecan (CPT-11) an active drug cancer. We planned short hepatic of CPT-11 to describe the toxicity, determine dose-limiting define doses be recommended for phase II studies. Patients Methods Fourteen patients with median substitution 30% (10-60%) were enrolled. All...
3607 Background: The combination of capecitabine plus long course radiotherapy (RT) is the standard preoperative therapy in cT3-4 cN+ rectal cancer. Pathologic Complete remission (pCR) can be considered as surrogate end point efficacy treatment terms disease free survival (DFS). Preclinical data points heavily toward a strong synergy between RT and immune treatments. Methods: This prospective phase II, open label, single arm, multi-centre study, conducted with support from AstraZeneca,...
<div>Abstract<p>Background: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5fluoruracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of metastatic colorectal cancer (mCRC) patients, with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able predict from immune-checkpoint inhibition in triple-negative breast cancer. In...
<p>Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and both treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control indicates FOLFOXIRI plus bevacizumab. Atezo bevacizumab atezolizumab.</p>
<p>Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and both treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control indicates FOLFOXIRI plus bevacizumab. Atezo bevacizumab atezolizumab.</p>
<p>Consort diagram of the study. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo bevacizumab and atezolizumab.</p>
<p>Consort diagram of the study. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo bevacizumab and atezolizumab.</p>
<p>Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and both treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control indicates FOLFOXIRI plus bevacizumab. Atezo bevacizumab atezolizumab.</p>
<p>Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and both treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control indicates FOLFOXIRI plus bevacizumab. Atezo bevacizumab atezolizumab.</p>